Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Immunotherapy;  Melanoma

Presenters

Judith Versluis

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

J.M. Versluis1, I.L.M. Reijers1, E.A. Rozeman1, A.C.J. van Akkooi2, W.J. van Houdt2, C. Bierman3, B.A. van de Wiel4, G.V. Long5, C.U. Blank1

Author affiliations

  • 1 Department Of Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), 1066 CX - Amsterdam/NL
  • 2 Department Of Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), 1066 CX - Amsterdam/NL
  • 3 Department Of Biometrics, Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), 1066 CX - Amsterdam/NL
  • 4 Department Of Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek (NKI-AVL), 1066 CX - Amsterdam/NL
  • 5 Department Of Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
More

Resources

Abstract 3230

Background

In stage III melanoma patients, adjuvant immune checkpoint inhibition (ICI) has shown to improve relapse free survival. However, preclinical and translational data suggest that neoadjuvant (neoadj) ICI might be more beneficial due to broader immune activation. In the OpACIN and OpACIN-neo trials with neoadj IPI+NIVO, high pathologic (path) response rates (pRR) were observed (78% and 77%, respectively). Furthermore, neoadj ICI could reduce tumor burden, making surgery less mutilating. In patients presenting with synchronous lymph node (LN) metastases, neoadj ICI might improve surgical resectability of both sites. To date, response of these primary melanoma lesions upon neoadj IPI+NIVO is not reported.

Methods

Here we report on four stage III melanoma patients with melanoma at the primary site and synchronous LN metastases that were treated with neoadj IP+NIVO.

Results

Four stage III melanoma patients were identified. In the OpACIN-neo trial, one patient treated with 2 courses IPI 1 mg/kg + NIVO 3 mg/kg showed a path partial response (33% viable tumor cells) in the in-scar recurrence and a complete response (CR) in the LN metastasis, and one patient treated with 2 courses IPI 3 mg/kg followed by 2 courses NIVO 3 mg/kg showed no pathological response in both the in-scar recurrence (60% viable tumor cells) and LN metastasis (59% vital tumor). In the PRADO extension cohort, one patient treated with 2 courses IPI 1 mg/kg + NIVO 3 mg/kg demonstrated a path CR in both the axillar LN metastases and the primary melanoma on digit 4 of his right hand, preventing finger amputation. The results of another PRADO patient with a large primary on the shoulder and axillar LN metastases are pending (expected June 2019).

Conclusions

Neoadjuvant IPI+NIVO induces comparable responses in LN metastases and at the primary melanoma location. In the light of the high LN response upon neoadj IPI+NIVO, postponing the resection of the primary or recurrent melanoma should be considered, improving surgical resectability and reducing morbidity.

Clinical trial identification

NCT02977052.

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute.

Funding

BMS.

Disclosure

E.A. Rozeman: Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: NanoString. A.C.J. van Akkooi: Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: MSD Merck; Advisory / Consultancy: Merck-Pfizer; Advisory / Consultancy: 4SC. G.V. Long: Advisory / Consultancy: Aduro; Advisory / Consultancy: Amgen; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Mass-Array; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche. C.U. Blank: Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: GSK; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: GenMab; Advisory / Consultancy: Lilly; Research grant / Funding (self): NanoString; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.